Why it matters
FDA is actively investing in how digital measures can support clinical research, which can strengthen evidence pathways for sensor-enabled endpoints and decentralized measurement.
Decision implication
Track funded projects, measure-validation methods, endpoint acceptability, and resulting guidance or precedents relevant to healthspan and remote measurement.
Who or what is affected
- FDA
- drug developers
- DHT developers
- researchers
- trial sponsors
Evidence and sources
E5 — official FDA source
P4L distinguishes the sourced event from the interpretation above. Participation, funding, proposed policy, or program inclusion does not by itself establish clinical effectiveness.
What P4L is watching next
- Awardees
- selected DHT modalities
- endpoints
- validation results
- new FDA guidance.